These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36758321)

  • 1. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
    Zhang J; Zhou N; Deng H; Chen X; Chen Q; Wang Q; Sun L; Wen Y; Cao X; Luo Z; Zhang J; Zhu W; Guo L
    Lung Cancer; 2023 Apr; 178():11-19. PubMed ID: 36758321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]   [Full Text] [Related]  

  • 3. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
    Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D
    Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer.
    Feng Y; Liu Y; Yuan M; Dong G; Zhang H; Zhang T; Chang L; Xia X; Li L; Zhu H; Xing P; Wang H; Shi Y; Wang Z; Hu X
    Cancer Res Treat; 2022 Jul; 54(3):753-766. PubMed ID: 34645133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
    Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
    J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Su Z; Wang Z; Ni X; Duan J; Gao Y; Zhuo M; Li R; Zhao J; Ma Q; Bai H; Chen H; Wang S; Chen X; An T; Wang Y; Tian Y; Yu J; Wang D; Xie XS; Bai F; Wang J
    Clin Cancer Res; 2019 Aug; 25(16):5049-5060. PubMed ID: 31113842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
    Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
    Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
    Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
    BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
    Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
    EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.